November 20, 2019
The Ministry of Health, Labor and Welfare (MHLW) on November 19 granted orphan drug designation for six compounds including Merck Biopharma’s c-MET inhibitor tepotinib and Bristol-Myers Squibb’s antidote andexanet alfa. Tepotinib, which has also been given sakigake fast-track designation, was...read more